efficacy of interferon-beta preceding sofosbuvir and ledipasvir combination therapy in genotype 1b HCV infected patients who failed to daclatasvir and asunaprevir therapy

efficacy of interferon-beta preceding sofosbuvir and ledipasvir combination therapy in genotype 1b HCV infected patients who failed to daclatasvir and asunaprevir therapy - efficacy of interferon-beta preceding sofosbuvir and ledipasvir combination therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018854

Enrollment

130

Registered

2015-09-14

Start date

2015-09-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

genotype 1b HCV infected patients who failed to daclatasvir and asunaprevir combination therapy

Interventions

Interferon-beta 300 MIU, intravenous injection was carried out for 14 days every 12 hours twice a day, and oral SOF / LDP treatment (Harvoni) a day in the morning once for 84 days.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients who failed to daclatsuvir and asunaprevir combination therapy

Exclusion criteria

Exclusion criteria: Less than the number of platelets 25 000 / mm3, ALT value of 500 U / mL or more

Design outcomes

Primary

Measure	Time frame
level of serum HCV-RNA titer at 12 and 24 weeks after the treatment	—

Countries

Japan

Contacts

Public ContactYoshihito Uchida

Saitama Medical University Department of Gastroenterology & Hepatology

y_uchida@saitama-med.ac.jp049-276-1198

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026